Penalty Amount
$96,500,000
Oregon and a multistate coalition announced a plan to distribute settlement funds to people who paid inflated prices for certain generic drugs. The release says a federal court granted preliminary approval of the distribution plan this month; it does not give the date of that approval, and the reported conduct concerns alleged antitrust violations rather than a privacy violation.
A federal court granted preliminary approval of a plan to distribute settlement funds, totaling approximately $96.5 million, to potentially affected consumers. Eligible purchasers may seek compensation for certain generic drugs bought between May 2009 and December 2019.
This release concerns alleged antitrust conduct, not privacy practices. In vendor, distribution, and customer agreements involving generic drugs or other competitively sensitive pricing, review clauses and related controls for prohibitions on price fixing, market allocation, and coordination with competitors; ensure each party retains independent pricing authority and restricts sharing competitively sensitive information. Review employee and executive policies, training, and record-retention provisions concerning competitor communications and trade association interactions. The release does not describe new privacy-specific contract requirements.
Entity
Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure
Industry
Healthcare"Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure"
"totaling approximately $96.5 million"
"unlawfully discourage competition, raise prices, and enforce a culture of collusion"
"This month, a federal court granted preliminary approval of a plan to undo the harm caused by these corporations."
"Oregon and a coalition of 47 other states and territories worked to hold these corporations accountable"
Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.
$96.5M
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.
An Oregon judge rejected RealPage’s attempt to have the state’s rent-pricing lawsuit dismissed, allowing the case to move forward. Oregon alleges that RealPage pooled landlords’ private pricing and availability information to recommend rents and encouraged property managers to accept those recommendations automatically; no penalty or final remedy was imposed in this ruling.
Oregon Attorney General Dan Rayfield joined a multistate coalition in filing a lawsuit challenging NHTSA’s rollback of fuel economy standards. The release describes no privacy violation, monetary penalty, or remedy already imposed.
$400.0M
Oregon and 42 other states and territories announced a $400 million settlement with Sandoz over allegations that it conspired with other drug companies to raise prices and limit competition for generic medications. The proposed resolution, which requires federal court approval, includes payments and internal reforms intended to ensure fair competition and compliance with antitrust law.
Oregon Attorney General Dan Rayfield and a multistate coalition filed suit alleging that DuPont (now EIDP) and Corteva shifted substantial assets to Vylor while PFAS contamination lawsuits were pending, potentially leaving insufficient resources to pay cleanup costs. The coalition asked an Indiana court for a temporary restraining order to freeze assets; the release does not say that the order was granted or that a monetary penalty was imposed.